The Company intends to focus on industries that complement its management team’s background and to capitalize on the ability of the management team to identify and acquire a business where the management team has extensive experience. Sectors the Company plans on exploring include the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors. Maxpro Capital is led by Chairman and CEO Chen, Hong-Jung (Moses), CFO Gau, Wey-Chuan (Albert), and CSO Song, Yung-Fong (Ron).
Total SPAC deal count for 2021 year-to-date is now 458. This offering is expected to close on Tuesday, October 12.
EF Hutton, a division of Benchmark Investments, LLC, is the sole book running manager for the offering. Nelson Mullins Riley & Scarborough LLP is serving as Issuer’s Counsel with Loeb & Loeb LLP serving as Underwriter’s Counsel. MaloneBailey, LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.